This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Down 13.9% in 4 Weeks, Here's Why Soleno Therapeutics, Inc. (SLNO) Looks Ripe for a Turnaround
by Zacks Equity Research
Soleno Therapeutics, Inc. (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Soleno Therapeutics (SLNO) Enters Oversold Territory
by Zacks Equity Research
Soleno Therapeutics (SLNO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients
by Zacks Equity Research
The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.
Catalyst (CPRX) Beats on Q4 Earnings, Revenues Rise Y/Y
by Zacks Equity Research
Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.
Soleno Therapeutics (SLNO) Is in Oversold Territory: What's Next?
by Zacks Equity Research
Soleno Therapeutics (SLNO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Soleno Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Soleno Therapeutics.
Soleno (SLNO) in Focus: Stock Moves 6.3% Higher
by Zacks Equity Research
Soleno (SLNO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Soleno (SLNO) to report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Soleno (SLNO) to provide its clinical program updates when its releases second-quarter 2020 results.
Translate Bio (TBIO) in Focus: Stock Moves 11.7% Higher
by Zacks Equity Research
Translate Bio (TBIO) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
Soleno (SLNO) Looks Good: Stock Adds 6.8% in Session
by Zacks Equity Research
Soleno (SLNO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Soleno Therapeutics, Inc. (SLNO) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Soleno Therapeutics, Inc. (SLNO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Implied Volatility Surging for Soleno Therapeutics (SLNO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Soleno Therapeutics (SLNO) stock based on the movements in the options market lately.
Jazz Pharma (JAZZ) Surpasses Q4 Earnings & Sales Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats fourth-quarter 2019 earnings and revenue estimates. It issues guidance for 2020.
Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study
by Zacks Equity Research
Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.
Capnia, Inc. (SLNO) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Capnia, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug
by Zacks Equity Research
The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.
La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza
by Zacks Equity Research
The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.
Will Capnia to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Capnia.
Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?
by Zacks Equity Research
During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.
Small Drug Stocks Outlook: Near-Term Prospects Encouraging
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaboration and M&A activity keep small drugmakers afloat in a competitive market.
Will Capnia Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Capnia.
Are You Looking for a Top Momentum Pick? Why Capnia, Inc. (SLNO) is a Great Choice
by Zacks Equity Research
Does Capnia, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.